医学
肝纤维化
纤维化
肝星状细胞
机制(生物学)
病态的
肝病
疾病
中医药
肝细胞
慢性肝病
药理学
生物信息学
病理
肝硬化
内科学
生物
替代医学
哲学
认识论
作者
Wei Wang,Y. Z. Lu,Mozuo NIAN,Qiuju Sheng,Chong ZHANG,Chao Han,Xiaoguang Dou,Yang Ding
标识
DOI:10.1016/s1875-5364(23)60443-1
摘要
Liver fibrosis is a pathological condition characterized by replacement of normal liver tissue with scar tissue, and also the leading cause of liver-related death worldwide. During the treatment of liver fibrosis, in addition to antiviral therapy or removal of inducers, there remains a lack of specific and effective treatment strategies. For thousands of years, Chinese herbal medicines (CHMs) have been widely used to treat liver fibrosis in clinical setting. CHMs are effective for liver fibrosis, though its mechanisms of action are unclear. In recent years, many studies have attempted to determine the possible mechanisms of action of CHMs in treating liver fibrosis. There have been substantial improvements in the experimental investigation of CHMs which have greatly promoted the understanding of anti-liver fibrosis mechanisms. In this review, the role of CHMs in the treatment of liver fibrosis is described, based on studies over the past decade, which has addressed the various mechanisms and signaling pathways that mediate therapeutic efficacy. Among them, inhibition of stellate cell activation is identified as the most common mechanism. This article provides insights into the research direction of CHMs, in order to expand its clinical application range and improve its effectiveness.
科研通智能强力驱动
Strongly Powered by AbleSci AI